SodaStream International Ltd. (SODA) Is At $72.15 Formed Wedge; Algorx Pharmaceuticals Has 1.35 Sentiment

Agile Therapeutics, Inc., a forward-thinking women's healthcare company, focuses on the development and commercialization of prescription contraceptive products for women. The company has market cap of $97.09 million. The Company’s lead product candidate is Twirla, also known as AG200-15, a once-weekly contraceptive patch, which completed Phase III clinical trials. It currently has negative earnings. The firm is also developing a pipeline of other new transdermal contraceptive products, including AG200-ER, a regimen that allows a woman to extend the length of her cycle; AG200-SP, which is a regimen designed to provide shorter lighter periods; and AG890, a progestin-only contraceptive patch intended for use by women who are unable or unwilling to take estrogen.

SodaStream International Ltd. (SODA) formed wedge up with $75.76 target or 5.00% above today’s $72.15 share price. SodaStream International Ltd. (SODA) has $1.58 billion valuation. The stock decreased 0.88% or $0.64 during the last trading session, reaching $72.15. About 182,430 shares traded. SodaStream International Ltd. (NASDAQ:SODA) has risen 180.89% since January 7, 2017 and is uptrending. It has outperformed by 164.19% the S&P500.

Among 4 analysts covering Sodastream International (NASDAQ:SODA), 1 have Buy rating, 0 Sell and 3 Hold. Therefore 25% are positive. Sodastream International has $60 highest and $16 lowest target. $25.60’s average target is -64.52% below currents $72.15 stock price. Sodastream International had 15 analyst reports since August 5, 2015 according to SRatingsIntel. As per Tuesday, October 3, the company rating was maintained by Jefferies. Jefferies maintained SodaStream International Ltd. (NASDAQ:SODA) on Monday, October 30 with “Hold” rating. The rating was initiated by Jefferies with “Hold” on Wednesday, December 16. The stock of SodaStream International Ltd. (NASDAQ:SODA) earned “Hold” rating by Susquehanna on Tuesday, August 1. Jefferies maintained it with “Hold” rating and $55.0 target in Wednesday, August 30 report. As per Thursday, June 29, the company rating was maintained by Jefferies. Canaccord Genuity maintained SodaStream International Ltd. (NASDAQ:SODA) on Wednesday, August 5 with “Hold” rating. The rating was upgraded by Susquehanna to “Positive” on Thursday, August 3. The stock of SodaStream International Ltd. (NASDAQ:SODA) earned “Hold” rating by Jefferies on Thursday, May 12. The firm has “Hold” rating by Jefferies given on Wednesday, October 12.

Analysts await SodaStream International Ltd. (NASDAQ:SODA) to report earnings on February, 21. They expect $0.78 EPS, up 9.86% or $0.07 from last year’s $0.71 per share. SODA’s profit will be $17.08M for 23.13 P/E if the $0.78 EPS becomes a reality. After $0.87 actual EPS reported by SodaStream International Ltd. for the previous quarter, Wall Street now forecasts -10.34% negative EPS growth.

Proquest Associates Iv Llc holds 22.62% of its portfolio in Agile Therapeutics, Inc. for 5.06 million shares. Caxton Corp owns 1.82 million shares or 8.26% of their US portfolio. Moreover, Aisling Capital Llc has 1.32% invested in the company for 1.80 million shares. The Sweden-based Investor Ab has invested 1.01% in the stock. Cormorant Asset Management Llc, a Massachusetts-based fund reported 1.25 million shares.

Analysts await Agile Therapeutics, Inc. (NASDAQ:AGRX) to report earnings on March, 14. They expect $-0.25 earnings per share, up 13.79% or $0.04 from last year’s $-0.29 per share. After $-0.22 actual earnings per share reported by Agile Therapeutics, Inc. for the previous quarter, Wall Street now forecasts 13.64% negative EPS growth.

The stock increased 1.07% or $0.03 during the last trading session, reaching $2.84. About 253,026 shares traded. Agile Therapeutics, Inc. (AGRX) has declined 48.71% since January 7, 2017 and is downtrending. It has underperformed by 65.41% the S&P500.